Pancreatic Cancer Research

ResearcherMonash Medical CentreActive in the last 2 years

Joanne Lundy

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0210-4930; OpenAlex author ID A5032596712. Sources: OpenAlex.

Their work

Papers
16 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
38
Papers, trials and grants by year

2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 4 papers · 2022: 2 papers · 2023: 3 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 16

  1. Cancer cell-intrinsic inflammasome protein ASC links innate immunity with mitochondrial metabolism in driving pancreatic cancer. Co-author DOI 10.1038/s41467-026-69398-w↗
  2. Endoscopic ultrasound molecular evaluation of pancreatic cancer trial to profile molecular landscape of inoperable pancreatic ductal adenocarcinoma. First author DOI 10.1055/a-2733-1068↗
  3. Assessing the impact of an intensive dietitian-led telehealth intervention focusing on nutritional adequacy, symptom control and optional supplemental jejunal … Co-author DOI 10.1186/s12937-025-01113-9↗
  4. A Humanized Patient-Derived Xenograft Model for Pancreatic Cancer. Co-author DOI 10.1007/978-1-0716-3858-3_8↗
  5. Evaluation of Needles in Endoscopic Ultrasound-Guided Tissue Acquisition of Pancreatic Cancer for Genetic Yield and Quality. Co-author DOI 10.7759/cureus.68431↗
  6. Endoscopic Ultrasound-Guided Fine-Needle Biopsies to Generate Preclinical Disease Models to Study Inflammation in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/978-1-0716-3331-1_4↗
  7. Relationship between circulating tumour DNA and skeletal muscle stores at diagnosis of pancreatic ductal adenocarcinoma: a cross-sectional study. Co-author DOI 10.1038/s41598-023-36643-x↗
  8. Circulating Tumor DNA Is an Accurate Diagnostic Tool and Strong Prognostic Marker in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000002239↗
  9. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and L… Co-author DOI 10.1200/po.21.00437↗
  10. KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation? First author DOI 10.3390/cells11193175↗
  11. TLR2 activation promotes tumour growth and associates with patient survival and chemotherapy response in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41388-021-01992-2↗
  12. Targeted Transcriptome and KRAS Mutation Analysis Improve the Diagnostic Performance of EUS-FNA Biopsies in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-1107↗
  13. EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy. Co-author DOI 10.3389/fonc.2021.770022↗
  14. The EUS molecular evaluation of pancreatic cancer: A prospective multicenter cohort trial. Co-author DOI 10.4103/eus-d-20-00230↗
  15. Murine- and Human-Derived Autologous Organoid/Immune Cell Co-Cultures as Pre-Clinical Models of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers12123816↗
  16. Reviewing the Utility of EUS FNA to Advance Precision Medicine in Pancreatic Cancer. First author DOI 10.3390/cancers10020035↗

Closest collaborators

The 25 strongest of 38 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Gerald Croagh · 15 shared papers, 2018–2026 · strength 2.82
  2. Brendan John Jenkins · 10 shared papers, 2018–2026 · strength 1.57
  3. John Raymond Zalcberg · 4 shared papers, 2021–2026 · strength 0.64
  4. Rav Sellahewa · 2 shared papers, 2023 · strength 0.48
  5. Owen McKay · 2 shared papers, 2022–2026 · strength 0.46
  6. Lauren Hanna · 2 shared papers, 2023–2025 · strength 0.42
  7. Marion Harris · 3 shared papers, 2021–2022 · strength 0.39
  8. Henry Shen · 2 shared papers, 2022–2024 · strength 0.38
  9. Belinda Lee · 2 shared papers, 2021–2026 · strength 0.33
  10. Manoop S. Bhutani · 2 shared papers, 2021–2026 · strength 0.33
  11. Charles H. C. Pilgrim · 2 shared papers, 2021–2025 · strength 0.28
  12. William Berry · 2 shared papers, 2018–2021 · strength 0.28
  13. Sean Michael Grimmond · 1 shared paper, 2026 · strength 0.23
  14. Yu Chinn Joshua Chey · 1 shared paper, 2026 · strength 0.23
  15. David Herrmann · 1 shared paper, 2026 · strength 0.23
  16. Brooke Pereira · 1 shared paper, 2026 · strength 0.23
  17. Paul Timpson · 1 shared paper, 2026 · strength 0.23
  18. Vinod Ganju · 1 shared paper, 2022 · strength 0.22
  19. Jonanthan Tiong · 1 shared paper, 2024 · strength 0.22
  20. Kate Furness · 1 shared paper, 2025 · strength 0.19
  21. Mahesh Iddawela · 1 shared paper, 2025 · strength 0.19
  22. Emma McShane · 1 shared paper, 2025 · strength 0.19
  23. David Goldstein · 1 shared paper, 2021 · strength 0.12
  24. Val Gebski · 1 shared paper, 2021 · strength 0.12
  25. Marina Pajic · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.